Amazentis announces new clinical findings and launches first consumer product with Mitopure (proprietary highly pure Urolithin A) in the USA.
Amazentis is an innovative life science company dedicated to employing breakthrough research and clinical science to bring advanced therapeutic nutrition products to life.
We employ rigorous science
to pioneer the discovery and clinical development of the next generation of naturally derived bioactives, starting with Mitopure™ (a proprietary highly pure Urolithin A). Our focus is the development of innovative products designed to meet the health needs of an aging population. Our current work builds on modulating Mitochondrial function.
We are improving muscle health
Our most advanced product targets the reversal of age-related muscle decline by improving the activity of mitochondria – the “powerhouse of the cell” – to optimize muscle function.
Society is aging. Worldwide,
it’s projected there will be more than 1 billion people over 65 years old by 2030.
A decline in skeletal muscle strength and overall function is a hallmark of aging. These changes can become debilitating and lead to a condition called sarcopenia, which is thought to affect 30% of elderly.
We are targeting a novel pathway
Our lead bioactive - a metabolite of pomegranates - has been demonstrated to trigger a highly effective biological mechanism of action that recycles and rejuvenates aging mitochondria via a process called mitophagy.
Patrick Aebischer, MD
Chairman and Co-Founder
Chris Rinsch, PhD
CEO and Co-Founder
Pierre Landolt
Co-Founder
Odile Rundquist, PhD
Thierry Lombard
Eric Lohrer